THALES
14.12.2022 10:01:51 CET | Business Wire | Press release
Thales, with its Sentinel Platform for License and Entitlement Management, has been awarded the Best Practices Frost & Sullivan Market Leadership Award in the global software license management market. Recognized among other companies that successfully deploy best practices, growth strategies, and strategic analytics across a value chain, Thales received the Market Leadership Award for achieving the greatest market share based on its outstanding performance, products, and services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005097/en/
©Thales
Frost & Sullivan’s global team of Growth Pipeline experts continually identifies and evaluates growth opportunities across multiple industries, technologies, and regions worldwide. The process involves the rigorous analysis of several nominees for each award category to determine the recipient, evaluating best practices criteria across two dimensions for each nominee. Thales was successful across several categories, including product differentiation, brand strength, growth strategy excellence, product quality, and implementation excellence.
Software licensing management (SLM) production has faced several roadblocks in its development in the current market. Software manufacturers and device makers regularly struggle to prevent access to unauthorised users while ensuring legitimate users can easily access and buy their solutions. The emergence of the COVID-19 pandemic and its aftermath, as well as high costs and lack of awarenesss, mean that despite its many benefits, SLM has not grown as exponentially as it should, especially in regions such as Asia and Latin America.
Thales is a recognized leader in the software monetization field, providing the most comprehensive platform and services for license and entitlement management and helping software-as-a-service (SaaS) companies accelerate their growth. With a team of 450 experts across more than 20 countries, including the United States, much of Europe, South Korea, China, Japan, and India, Thales solidifies its position as a leader in the software license management market.
“Thales provides the most comprehensive platform for software enforcement and hardware enforcement and is focused on solutions to help the SaaS market scale quickly,” said Mukul Krishna, Global Practice Head, Frost & Sullivan.
Thales offers a comprehensive suite of software monetization solutions, using a sophisticated entitlement management capability to address any combination of SaaS, on-premises, and device-based requirements. The company provides customers with the flexibility to create, manage, and deploy custom licenses for products across distribution channels and pricing models to meet evolving customer needs. Additionally, the company enables the tracking of customer licenses; prevents their reproduction, distribution, and unauthorized use; and protects license IP theft through encryption and anti-debugging.
With its SaaS services, application programming interfaces (APIs) and web services, Thales lowers ownership cost and the high expense of customization for an elevated customer experience. In a fiercely competitive and ever-changing market, Thales has made its way to the top with an effective growth strategy and resilience and offers optimal services at a global scale.
Thales’s software monetization solutions are available for use today. For more information, download the Frost and Sullivan Growth Opportunity Analysis 2022 report or visit: https://cpl.thalesgroup.com/software-monetization.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005097/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom